Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
BridgeBio finds, develops, and delivers breakthrough medicines for genetic disease...
BridgeBio finds, develops, and delivers breakth...
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, dev...
Cytokinetics is a late-stage biopharmaceutical ...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.